APGE - NASDAQ
Apogee Therapeutics, Inc.
$84.19
+3.0%Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.
At a Glance
Live SnapshotApogee Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Apogee Therapeutics, Inc. Cash Flow Statement
APGE • NASDAQ
| Apogee Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
OPERATING ACTIVITIES | ||||
-255.8M | -182.1M | -84M | -39.8M | |
1.4M | 189K | 0.0 | 0.0 | |
46.3M | 23.3M | 6.1M | 2.1M | |
-3.8M | -10.5M | -3M | 11.4M | |
-15.5M | -2M | 6.1M | 9.8M | |
-227.5M | -171.2M | -74.8M | -16.4M | |
INVESTING ACTIVITIES | ||||
-5.1M | -1.2M | -167K | (0.0) | |
-642.3M | -649.5M | -303.7M | (0.0) | |
467.9M | 350.1M | 30M | 0.0 | |
-179.6M | -300.5M | -273.9M | (0.0) | |
FINANCING ACTIVITIES | ||||
396.5M | 493.5M | 315.4M | 168.3M | |
0.0 | 1.6M | 0.0 | 0.0 | |
396.5M | 495.1M | 315.4M | 168.3M | |
CASH FLOW SUMMARY | ||||
-10.5M | 23.5M | -33.3M | 151.9M | |
142.1M | 118.6M | 151.9M | 0.0 | |
131.5M | 142.1M | 118.6M | 151.9M | |
-232.6M | -172.3M | -74.9M | -16.4M |
SEC Filings
APGE - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 27, 2026 | May 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 27, 2026 | May 27, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 11, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 11, 2026 | May 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 24, 2026 | April 21, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 24, 2026 | June 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 25, 2026 | March 24, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 23, 2026 | March 23, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 02, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 02, 2026 | March 02, 2026 | 2026 |
Related Guides
Continue your APGE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.